abstract |
Provided herein are methods of predicting a likelihood of survival following treatment with AA (abiraterone acetate) and prednisone in a patient having CRPC (castration resistant prostate cancer), by detection of mRNA levels of ANLN, HDS17B10,NUSAP1,SF1,SRD5A1,UBE2C,CYP17A1 and cofactors and androgen controlled group proteins. |